Allstocks.com's Bulletin Board Post A Reply
my profile login | register | search | faq | forum home

» Allstocks.com's Bulletin Board » Hot Stocks Free for All ! » ATHX Athersys, Inc. » Post A Reply

Post A Reply
Login Name:
Password:
Message Icon: Icon 1     Icon 2     Icon 3     Icon 4     Icon 5     Icon 6     Icon 7    
Icon 8     Icon 9     Icon 10     Icon 11     Icon 12     Icon 13     Icon 14    
Message:

HTML is not enabled.
UBB Code™ is enabled.

 

Instant Graemlins Instant UBB Code™
Smile   Frown   Embarrassed   Big Grin   Wink   Razz  
Cool   Roll Eyes   Mad   Eek!   Confused   BadOne  
Good Luck   More Crap   Wall Bang   Were Up   Were Down    
Insert URL Hyperlink - UBB Code™   Insert Email Address - UBB Code™
Bold - UBB Code™   Italics - UBB Code™
Quote - UBB Code™   Code Tag - UBB Code™
List Start - UBB Code™   List Item - UBB Code™
List End - UBB Code™   Image - UBB Code™

What is UBB Code™?
Options


Disable Graemlins in this post.


 


T O P I C     R E V I E W
BooDog  - posted
1.90. 1.97ah close yesterday.

Check your charts, broke its 3 year trend line. How much longer it can stay in the power zone is the question. If it doesn't gap up i see a very small gap @ 1.87.

http://www.nasdaq.com/symbol/athx/ownership-summary
31% institutional.
The registrant had 53,508,632 shares of common stock outstanding on March 1, 2013. 100M Authorized.
http://www.sec.gov/Archives/edgar/data/1368148/000119312513103341/d444950d10k.ht m


Athersys to Present at Regen Med Investor Day 2013 in New York
22 hours 16 minutes ago - GlobeNewswire via Comtex
Athersys, Inc. (Nasdaq:ATHX) announced today that Chairman and CEO, Gil Van Bokkelen, will present at the 2013 Regen Med Investor Day to be held Wednesday, April 17, 2013 in New York City.

Organized by the Alliance for Regenerative Medicine (ARM) in partnership with leading financial firms Burrill & Company, Maxim Group and Piper Jaffray, this flagship event features sixteen of the regenerative medicine field's leading small- and mid-cap companies. In addition, there will be disease indication focused discussions between key opinion leaders, top analysts and senior executives from the sector and keynote style talks by Jeff Jonas, President of Shire Regenerative Medicine, and Kieran Murphy, President and CEO, GE Healthcare Life Sciences.

The following are specific details regarding Athersys' presentation at the conference:

Event: ARM's Regen Med Investor Day
Date: April 17, 2013
Time: 1:15 p.m. EDT
Location: Harmonie Club, 4 East 60th Street, New York, NY 10022
A live video webcast of the company presentations will be available at: http://alliancerm.org/rmdaywebcast and will also be published on ARM's website shortly after the event.

In addition to the corporate presentation, Dr. Van Bokkelen will also participate in a panel that will discuss how advanced approaches in regenerative medicine are being developed to address significant unmet medical needs in the neurological area. Athersys is focused on the development of MultiStem to treat acute and chronic neurological conditions, including stroke, traumatic brain injury, multiple sclerosis and spinal cord injury, as well as other programs.

Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending please contact Laura Parsons at lparsons@alliancerm.org. Please visit http://alliancerm.org/event/regen-med-investor-day for more information.

About Athersys

Athersys is a clinical stage biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product platform for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas. The Company currently has several clinical stage programs involving MultiStem, including treatment of inflammatory bowel disease, ischemic stroke, damage caused by myocardial infarction, and for the prevention of graft versus host disease. Athersys has also developed a diverse portfolio that includes other technologies and product development opportunities, and has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available at www.athersys.com.

Use this to review the PR's http://ir.athersys.com/releases.cfm
Zacks and yahoo are difficult to track news on ATHX since zacks ties so many stocks together.
 
BooDog  - posted
Make that Institutions 36.70%
http://investors.morningstar.com/ownership/shareholders-overview.html?t=ATHX® ion=USA&culture=en-us
iShares Russell Microcap Index 78,429 04/11/2013
 
BooDog  - posted
ATHX 1.96 +0.06 1.96 1.97 477,675 1.83 1.98

gap filled.
 
BooDog  - posted
2.418 HOD Trailing stop kicked me out 2.37.

[Were Up] [Were Up]
 
BooDog  - posted
Dipped back to 1.92, was thinking it would hit 1.90, then if that didn't hold 1.70 theeeeen 1.50.
Back to 1.98 now though. i have some @ 2.04.
 



Contact Us | Allstocks.com Message Board Home

© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share